Abstract

AIM: Our purpose was to examine the total antioxidant status (TAS) in subjects with metabolic syndrome (MS) subdivided according to the presence or not of diabetes mellitus.METHODS:We enrolled 106 subjects (45 women, 61 men) with MS subsequently subdivided in diabetics (14 women, 29 men) and nondiabetics (31 women, 29 men). TAS was obtained using an Assay kit which relies on the ability of plasma antioxidant substances to inhibit the oxidation of 2,2'-azino-bis(3-ethylbenzthiazoline sulfonic acid) to the radical ABTS+.RESULTS:In the group of MS subjects a significant decrease in TAS (p<0.05) in comparison with normal controls was evident. This difference was present between normal subjects and nondiabetic subjects with MS (p<0.001) but not between normal and diabetic subjects with MS. Examining the linear regression among TAS, age, anthropometric profile, blood pressure values and glycometabolic pattern, conflicting data were found.CONCLUSIONS:Although we know that TAS includes several enzymatic and non enzymatic antioxidants, we retain that the difference observed in the two subgroups of subjects with MS must be looked in particular into two pathophysiological aspects regarding bilirubin and uric acid.
Lingua originaleEnglish
pagine (da-a)166-169
Numero di pagine4
RivistaDIABETES &amp; METABOLIC SYNDROME
Volume8
Stato di pubblicazionePublished - 2014

Fingerprint

Antioxidants
Sulfonic Acids
Uric Acid
Bilirubin
Linear Models
Diabetes Mellitus
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cita questo

@article{5a1d6812ef16410f8b837b0d3f42d2fd,
title = "Behavior of the total antioxidant status in a group of subjects with metabolic syndrome.",
abstract = "AIM: Our purpose was to examine the total antioxidant status (TAS) in subjects with metabolic syndrome (MS) subdivided according to the presence or not of diabetes mellitus.METHODS:We enrolled 106 subjects (45 women, 61 men) with MS subsequently subdivided in diabetics (14 women, 29 men) and nondiabetics (31 women, 29 men). TAS was obtained using an Assay kit which relies on the ability of plasma antioxidant substances to inhibit the oxidation of 2,2'-azino-bis(3-ethylbenzthiazoline sulfonic acid) to the radical ABTS+.RESULTS:In the group of MS subjects a significant decrease in TAS (p<0.05) in comparison with normal controls was evident. This difference was present between normal subjects and nondiabetic subjects with MS (p<0.001) but not between normal and diabetic subjects with MS. Examining the linear regression among TAS, age, anthropometric profile, blood pressure values and glycometabolic pattern, conflicting data were found.CONCLUSIONS:Although we know that TAS includes several enzymatic and non enzymatic antioxidants, we retain that the difference observed in the two subgroups of subjects with MS must be looked in particular into two pathophysiological aspects regarding bilirubin and uric acid.",
author = "Baldassare Canino and Gregorio Caimi and Maurizio Averna and {Lo Presti}, Rosalia and Eugenia Hopps",
year = "2014",
language = "English",
volume = "8",
pages = "166--169",
journal = "DIABETES &amp; METABOLIC SYNDROME",
issn = "1871-4021",

}

TY - JOUR

T1 - Behavior of the total antioxidant status in a group of subjects with metabolic syndrome.

AU - Canino, Baldassare

AU - Caimi, Gregorio

AU - Averna, Maurizio

AU - Lo Presti, Rosalia

AU - Hopps, Eugenia

PY - 2014

Y1 - 2014

N2 - AIM: Our purpose was to examine the total antioxidant status (TAS) in subjects with metabolic syndrome (MS) subdivided according to the presence or not of diabetes mellitus.METHODS:We enrolled 106 subjects (45 women, 61 men) with MS subsequently subdivided in diabetics (14 women, 29 men) and nondiabetics (31 women, 29 men). TAS was obtained using an Assay kit which relies on the ability of plasma antioxidant substances to inhibit the oxidation of 2,2'-azino-bis(3-ethylbenzthiazoline sulfonic acid) to the radical ABTS+.RESULTS:In the group of MS subjects a significant decrease in TAS (p<0.05) in comparison with normal controls was evident. This difference was present between normal subjects and nondiabetic subjects with MS (p<0.001) but not between normal and diabetic subjects with MS. Examining the linear regression among TAS, age, anthropometric profile, blood pressure values and glycometabolic pattern, conflicting data were found.CONCLUSIONS:Although we know that TAS includes several enzymatic and non enzymatic antioxidants, we retain that the difference observed in the two subgroups of subjects with MS must be looked in particular into two pathophysiological aspects regarding bilirubin and uric acid.

AB - AIM: Our purpose was to examine the total antioxidant status (TAS) in subjects with metabolic syndrome (MS) subdivided according to the presence or not of diabetes mellitus.METHODS:We enrolled 106 subjects (45 women, 61 men) with MS subsequently subdivided in diabetics (14 women, 29 men) and nondiabetics (31 women, 29 men). TAS was obtained using an Assay kit which relies on the ability of plasma antioxidant substances to inhibit the oxidation of 2,2'-azino-bis(3-ethylbenzthiazoline sulfonic acid) to the radical ABTS+.RESULTS:In the group of MS subjects a significant decrease in TAS (p<0.05) in comparison with normal controls was evident. This difference was present between normal subjects and nondiabetic subjects with MS (p<0.001) but not between normal and diabetic subjects with MS. Examining the linear regression among TAS, age, anthropometric profile, blood pressure values and glycometabolic pattern, conflicting data were found.CONCLUSIONS:Although we know that TAS includes several enzymatic and non enzymatic antioxidants, we retain that the difference observed in the two subgroups of subjects with MS must be looked in particular into two pathophysiological aspects regarding bilirubin and uric acid.

UR - http://hdl.handle.net/10447/98683

M3 - Article

VL - 8

SP - 166

EP - 169

JO - DIABETES &amp; METABOLIC SYNDROME

JF - DIABETES &amp; METABOLIC SYNDROME

SN - 1871-4021

ER -